Eylea against Eylea HDInsight
How fast is Regeneron's Eylea losing to Vabysmo and biosimilars?
| Date | EYLEA HD | EYLEA |
|---|---|---|
| 2023-09-30 | 42.7M | 1.45B |
| 2024-03-31 | 200.0M | 1.20B |
| 2024-06-30 | 304.2M | 1.23B |
| 2024-09-30 | 392.3M | 1.14B |
| 2025-03-31 | 306.8M | 736.0M |
| 2025-06-30 | 393.2M | 754.3M |
| 2025-09-30 | 430.6M | 680.6M |
| 2026-03-31 | 468.4M | 473.1M |
| 2026-06-30 | 596.3M | 412.2M |
→EYLEA HD sold $596M in the US in Q2 2026 and the original EYLEA $412M, against $43M of EYLEA HD in Q3 2023.
Source: SEC EDGAR (10-Q and 10-K) · as at 2026-06-30
Where this comes from
- Source: SEC EDGAR (10-Q and 10-K) (filing)
- Which in turn reads: The company's 10-Q and 10-K
- How current: As at 2026-06-30 · checked every 91 days
- What we hold: 9 observations, from 2023-09-30 to 2026-06-30
- Attribution: Read from the company's 10-Q and 10-K as filed with the SEC. Public domain; linked per figure, not reproduced.